Study of Double-Targeting Nanoparticles Loaded With MCL-1 siRNA and Dexamethasone for Adjuvant-induced Arthritis Therapy.
In this study, HA-coated pH-responsive nanoparticles loaded with MCL-1 small interfering RNA (siRNA) and dexamethasone (HNPs/MD) were developed for RA treatment. The HNPs/MD had a mean particle size of 117.07 ± 2.21 nm and zeta potential of 15.53 ± 1.06 mV. The release rates of both MCL-1 siRNA and dexamethasone from the HNPs/MD at pH 4.5 and 6.0 were higher than those at pH 7.4, indicating that the nanoparticles were acid-sensitive. Cytotoxicity assays showed that compared with single drug loaded nanoparticles, the HNPs/MD showed higher cytotoxicity to activated macrophages. The superior therapeutic effect of HNPs/MD was demonstrated in an adjuvant-induced arthritis rat model. These findings indicate that pH-sensitive and HA-targeting co-delivery nanoparticles provide a new direction for the therapy of RA.
PMID: 32681961 [PubMed - as supplied by publisher]
Source: European Journal of Pharmaceutics and Biopharmaceutics - Category: Drugs & Pharmacology Authors: Li X, Yu C, Meng X, Hou Y, Cui Y, Zhu T, Li Y, Teng L, Sun F, Li Y Tags: Eur J Pharm Biopharm Source Type: research
More News: Arthritis | Dexamethasone | Drugs & Pharmacology | Gene Therapy | Genetics | Men | Nanotechnology | Rheumatoid Arthritis | Rheumatology | Science | Study